Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $32,542.65 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 10,331 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.15, for a total value of $32,542.65. Following the completion of the transaction, the chief executive officer now owns 3,775,019 shares of the company’s stock, valued at $11,891,309.85. This represents a 0.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Checkpoint Therapeutics Price Performance

Shares of CKPT traded down $0.10 during mid-day trading on Tuesday, reaching $3.13. 851,190 shares of the company’s stock traded hands, compared to its average volume of 885,885. The stock has a market cap of $152.84 million, a P/E ratio of -1.70 and a beta of 1.36. The stock’s 50-day moving average is $3.39 and its two-hundred day moving average is $2.99. Checkpoint Therapeutics, Inc. has a 12 month low of $1.38 and a 12 month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Research analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Lake Street Capital lifted their price objective on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a report on Monday, December 16th. Finally, D. Boral Capital initiated coverage on Checkpoint Therapeutics in a report on Monday, January 13th. They set a “buy” rating and a $9.00 price target for the company.

Institutional Trading of Checkpoint Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp boosted its position in Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after acquiring an additional 23,000 shares in the last quarter. Geode Capital Management LLC boosted its position in Checkpoint Therapeutics by 41.2% during the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares in the last quarter. Magnus Financial Group LLC boosted its position in Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 4,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Checkpoint Therapeutics by 160.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after acquiring an additional 80,000 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in Checkpoint Therapeutics during the 3rd quarter valued at $148,000. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.